Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study Comparing Effects of Ointments with Clotrimazole and Betamethasone Dipropionate for Patients with Moderate to Severe Skin Yeast Infections

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of two ointments for treating candidiasis of the skin, which is a type of skin infection caused by yeast fungi. The study involves patients with moderate to severely inflamed skin due to this infection. The trial will compare the effectiveness and safety of a new ointment called Mecloderm, which contains the active substances clotrimazole and betamethasone dipropionate, against an existing ointment known as Lotricomb, which contains the same active substances. Additionally, a third ointment without any active substances, referred to as a vehicle, will also be used for comparison.

The purpose of the study is to assess how well these ointments work in reducing the symptoms of the infection and to ensure they are safe for use. Participants in the study will apply one of the ointments to their skin as directed. The study will last for a period of two weeks, during which the participants will be monitored to see how their symptoms change over time. The study will involve several visits to check the progress and gather information on the effectiveness of the treatment.

Throughout the study, the participants' skin condition will be evaluated by both the study investigators and the participants themselves. The main goal is to determine which ointment is most effective in treating the infection and to ensure that it is safe for patients to use. The study will also look at whether the infection returns after treatment and how the participants feel about the treatment's success.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria, including age, diagnosis of skin infection, and other health parameters.

    Consent is required after receiving detailed information about the study.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the severity of the skin condition. This includes a clinical examination and a swab test to confirm the presence of yeast fungi.

  3. Step 3

    Treatment phase

    Participants are randomly assigned to one of three treatment groups: Mecloderm Ointment, Lotricomb Ointment, or a vehicle ointment without active substances.

    The ointments are applied to the skin as directed, typically for a duration of 14 days.

    Mecloderm Ointment contains clotrimazole (10 mg/g) and betamethasone dipropionate (0.64 mg/g).

  4. Step 4

    Follow-up visits

    Follow-up visits are scheduled to monitor progress and assess the effectiveness of the treatment.

    These visits include clinical evaluations and possibly additional swab tests to check for the presence of fungi.

  5. Step 5

    End of treatment evaluation

    At the end of the treatment period, a main examination is conducted to determine treatment success.

    Success is defined by a reduction in clinical symptoms and a negative result for fungal presence.

  6. Step 6

    Final examination

    A final examination is performed to evaluate the overall therapeutic success and to check for any signs of relapse or re-infection.

    The results from this examination contribute to the overall assessment of the treatment's efficacy and safety.

Who can join the trial?

8 criteria

  • Women and men who are **18 years or older** can participate.
  • Participants must provide **written consent** after being fully informed about the study by a doctor or a qualified team member.
  • Participants must have a **diagnosis of candidiasis of the skin**, which is a type of skin infection, based on visible symptoms.
  • A **positive test result** from a skin swab must show at least a moderate number of fungi under a microscope.
  • The total score of all clinical symptoms like **redness, fluid discharge, burning sensation, and skin softening** must be **7 or higher**.
  • The severity of **redness and fluid discharge** must be at least moderate, meaning a score of **2 or higher**.
  • Women who can have children must use a **highly effective birth control method** throughout the study.
  • Women who can have children must have a **negative pregnancy test** before starting the study.

Who cannot join the trial?

6 criteria

  • Patients who are allergic to any of the ingredients in the ointment cannot participate. An allergy is when your body reacts badly to something that is usually harmless.
  • Patients with other skin infections that are not caused by the fungus Candida cannot participate. Candida is a type of fungus that can cause infections.
  • Patients who are pregnant or breastfeeding cannot participate. This is to ensure the safety of both the mother and the baby.
  • Patients who have used similar treatments recently may not be eligible. This is to make sure the study results are accurate.
  • Patients with certain medical conditions that might interfere with the study cannot participate. This is to ensure the safety of the patient and the accuracy of the study.
  • Patients who are unable to follow the study instructions or attend the required visits cannot participate. This is important for the study to be conducted properly.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Mecloderm® Ointment

    is a new ointment being tested for its effectiveness and safety in treating skin inflammation caused by candidiasis. It contains two active ingredients: clotrimazole, which helps fight fungal infections, and betamethasone dipropionate, which reduces inflammation and itching.

  • Lotricomb® Ointment

    is an existing medication used as a reference in the study. It is also used to treat skin inflammation and infections. Like Mecloderm®, it contains clotrimazole to combat fungal infections and betamethasone dipropionate to alleviate inflammation and itching.

What is already known about the treatment

  • Mecloderm® Ointment

    This medication is applied topically as an ointment to treat moderate to severely inflamed candidiasis of the skin. It is currently being studied in clinical trials to assess its efficacy and safety compared to other treatments. The main therapeutic indication is for skin infections caused by Candida. Mecloderm® combines clotrimazole, an antifungal agent that disrupts the cell membrane of fungi, with betamethasone dipropionate, a corticosteroid that reduces inflammation. It is classified pharmacologically as a combination antifungal and corticosteroid medication.

  • Lotricomb® Ointment

    This ointment is also applied topically and is used to treat skin conditions like moderate to severely inflamed candidiasis. It is an established treatment and serves as a reference in clinical trials. The main therapeutic indication is for fungal skin infections with inflammation. Lotricomb® contains clotrimazole, which works by damaging the fungal cell membrane, and betamethasone dipropionate, which helps reduce inflammation. It is classified as a combination antifungal and corticosteroid medication.

Investigated diseases

Candidiasis of the Skin – Candidiasis of the skin is a fungal infection caused by the overgrowth of Candida species, commonly Candida albicans. It typically affects warm, moist areas of the body, such as the armpits, groin, and under the breasts. The condition is characterized by red, inflamed patches that may be itchy or painful. In moderate to severe cases, the skin may become cracked or develop blisters. The infection can spread to other areas if not managed properly. It is more common in individuals with weakened immune systems or those with certain medical conditions.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-501415-14-00Protocol code21-01/ClotriBet-SEstimated enrolment552 patientsSponsorDermapharm AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.